National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 60878-60879 [2018-25789]
Download as PDF
<![CDATA[
60878
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
Child Care and Indian Child Care
Worker Positions (OMB No. 0917–0028).
Type of Information Collection Request:
Extension, without revision, of currently
approved information collection, 0917–
0028, Addendum to Declaration for
Federal Employment, Child Care and
Indian Child Care Worker Positions.
There are no program changes or
adjustments in burden hours. Form(s):
Addendum to Declaration for Federal
Employment, Child Care and Indian
Child Care Worker Positions. Need and
Use of Information Collection: This is a
request for approval of the collection of
information as required by section 408
of the Indian Child Protection and
Family Violence Prevention Act, Public
Law (Pub. L.) 101–630, 104 Stat. 4544,
and 25 United States Code (U.S.C.)
§§ 3201–3210.
The IHS is required to compile a list
of all authorized positions within the
IHS where the duties and
responsibilities involve regular contact
with, or control over, Indian children;
and to conduct an investigation of the
character of each individual who is
employed, or is being considered for
employment, in a position having
regular contact with, or control over,
Indian children. 25 U.S.C. 3207(a)(1)
and (2). Title 25 U.S.C. 3207(a)(3)
requires regulations prescribing the
minimum standards of character for
individuals appointed to positions
involving regular contact with, or
control over, Indian children, and
section 3207(b) provides that such
standards shall ensure that no such
individuals have been found guilty of,
or entered a plea of nolo contendere or
guilty to any felonious offense, or any
two or more misdemeanor offenses,
under Federal, State, or Tribal law
involving crimes of violence; sexual
assault, molestation, exploitation,
contact or prostitution; crimes against
persons; or offenses committed against
children.
In addition, 34 U.S.C. 20351 (formerly
codified at 42 U.S.C. 13041, which was
transferred to 34 U.S.C. 20351) requires
each agency of the Federal Government,
and every facility operated by the
Federal Government (or operated under
contract with the Federal Government),
that hires (or contracts for hire)
individuals involved with the provision
of child care services to children under
the age of 18 to assure that all existing
and newly hired employees undergo a
criminal history background check. The
background investigation is to be
initiated through the personnel program
of the applicable Federal agency. This
section requires employment
applications for individuals who are
seeking work for an agency of the
Federal Government, or for a facility or
program operated by (or through
contract with) the Federal Government,
in positions involved with the provision
of child care services to children under
the age of 18, to contain a question
asking whether the individual has ever
been arrested for or charged with a
crime involving a child, and if so,
requiring a description of the
disposition of the arrest or charge.
Affected Public: Individuals and
households. Type of Respondents:
Individuals.
The table below provides: Types of
data collection instruments, Estimated
number of respondents, Number of
responses per respondent, Average
burden hour per response, and Total
annual burden hour(s).
ESTIMATED ANNUAL BURDEN HOURS
Number of
respondents
Data collection instrument(s)
Total annual
burden
responses
(in hours)
Addendum to Declaration for Federal Employment (OMB 0917–0028) .........
3,000
1
12/60
600
Total ..........................................................................................................
3,000
........................
........................
600
There are no Capital Costs, Operating
Costs, and/or Maintenance Costs to
report.
Dated: November 19, 2018.
Michael D. Weahkee,
Assistant Surgeon General, U.S. Public Health
Service, Principal Deputy Director, Indian
Health Service.
[FR Doc. 2018–25819 Filed 11–26–18; 8:45 am]
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
amozie on DSK3GDR082PROD with NOTICES1
Average
burden per
response
(in hours)
Number of
responses per
respondent
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
VerDate Sep<11>2014
17:45 Nov 26, 2018
Jkt 247001
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Centers for AIDS Research
and Developmental Centers for AIDS
Research (P30).
Date: December 11–12, 2018.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Audrey O. Lau, Ph.D.,
MPH, Acting Senior Scientific Review
Officer, AIDS Review Branch, SRP, Rm.
3E70, National Institutes of Health, NIAID,
5601 Fishers Lane, MSC 9834, Rockville, MD
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
20852–9834, 240–669–2081, audrey.lau@
nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: December 19, 2018.
Time: 12:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Rockville, MD 20892–9823, (240) 669–5023,
fdesilva@niaid.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: December 20, 2018.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\27NON1.SGM
27NON1
Federal Register / Vol. 83, No. 228 / Tuesday, November 27, 2018 / Notices
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
Room #3E72A, National Institutes of Health/
NIAID, 5601 Fishers Lane, MSC 9823,
Rockville, MD 20892–9823, (240) 669–5023,
fdesilva@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 20, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–25789 Filed 11–26–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Barry Buchbinder, Ph.D., 240–627–
3678; barry.buchbinder@nih.gov.
Licensing information and copies of the
U.S. patent application listed below
may be obtained by communicating
with the indicated licensing contact at
the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
MD 20852; tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
amozie on DSK3GDR082PROD with NOTICES1
SUMMARY:
Recombinant HIV–1 Envelope Proteins
and Their Use
Description of Technology
An effective human
immunodeficiency virus type 1 (HIV–1)
vaccine has long been sought to contend
VerDate Sep<11>2014
17:45 Nov 26, 2018
Jkt 247001
with the Acquired Immunodeficiency
Syndrome (AIDS) pandemic.
One approach researchers have taken
to elicit broadly neutralizing antibodies
against HIV–1 is to stabilize the
structurally flexible HIV–1 envelope
(Env) trimer. Researchers stabilized the
Env trimer in a conformation that
displays predominantly broadly
neutralizing epitopes and few nonneutralizing epitopes. Currently, BG505
DS–SOSIP is a leading vaccine
candidate with the desired
conformation and antigenicity.
Ideally, to be useful as a vaccine, such
a conformationally fixed Env
immunogen should have high
thermostability and should remain in
the desired antigenic state, even in the
presence of CD4, a glycoprotein found
on the surface of immune cells.
Researchers at the Vaccine Research
Center (VRC) of the National Institute of
Allergy and Infectious Diseases (NIAID)
undertook efforts to improve the
properties of BG505 DS–SOSIP for use
as a vaccine. The VRC researchers
introduced three additional mutations
to further stabilize BG505 DS–SOSIP in
the vaccine-preferred prefusion-closed
conformation and refer to the
engineered BG505 DS–SOSIP as BG505
DS–SOSIP.3mut. Experiments showed
that these modifications conferred
improved thermostability that will
allow easier transport and storage of
BG505 DS–SOSIP.3mut compared to
BG505 DS–SOSIP. In addition, BG505
DS–SOSIP.3mut has lower antigenicity
toward non/weak neutralizing
antibodies compared to BG505 DS–
SOSIP, which suggests that it could
potentially elicit higher neutralization
titer by targeting only broadly
neutralizing antibodies. With improved
antigenicity and stability, this version
may have utility as an HIV–1
immunogen or in other antigen-specific
contexts, such as for use with B-cell
probes.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications
• Vaccine—to elicit potent
neutralizing antibodies against the HIV–
1 Env glycoprotein.
• Probes—to identify broad and
potent HIV–1-neutralizing antibodies.
Competitive Advantages
Compared to previous engineered Env
trimer versions:
• 300-fold reduction in CD4-binding
affinity.
• Reduced binding affinity to
ineffective HIV–1 antibodies.
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
60879
• Increase in melting temperature (10
degrees over BG505 SOSIP).
Development Stage: In vivo testing
(rodents).
Inventors: Peter Kwong (NIAID), John
Mascola (NIAID), Gwo-Yu Chuang
(NIAID), Cheng Cheng (NIAID), Hui
Geng (NIAID), Yongping Yang (NIAID)
and Jeffrey C. Boyington (NIAID).
Intellectual Property: HHS Reference
Number E–240–2017 includes U.S.
Provisional Patent Application Number
62/579,973 filed 10/16/2017.
Related Intellectual Property: HHS
Reference Number E–187–2014 includes
U.S. Provisional Patent Application
Number 62/046,059 filed 9/4/2014, U.S.
Provisional Patent Application Number
62/136,480 filed 3/21/2015, PCT
Application No. PCT/US2015/048729
filed 9/4/2015, US Patent Application
15/508,885 filed 3/3/2017, EP Patent
Application Number 15766697.5 filed
3/29/2017.
Licensing Contact: Barry Buchbinder,
Ph.D., 240–627–3678;
barry.buchbinder@nih.gov.
Dated: November 14, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2018–25787 Filed 11–26–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; NCI SPORE
I (P50) Review.
Date: January 29–30, 2019.
Time: 8:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Washington/Rockville Hotel,
1750 Rockville Pike, Rockville, MD 20850.
E:\FR\FM\27NON1.SGM
27NON1
]]>Agencies
[Federal Register Volume 83, Number 228 (Tuesday, November 27, 2018)]
[Notices]
[Pages 60878-60879]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-25789]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Centers for AIDS Research and
Developmental Centers for AIDS Research (P30).
Date: December 11-12, 2018.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Audrey O. Lau, Ph.D., MPH, Acting Senior
Scientific Review Officer, AIDS Review Branch, SRP, Rm. 3E70,
National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9834,
Rockville, MD 20852-9834, 240-669-2081, [email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: December 19, 2018.
Time: 12:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room #3E72A, National Institutes of Health/NIAID, 5601
Fishers Lane, MSC 9823, Rockville, MD 20892-9823, (240) 669-5023,
[email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01).
Date: December 20, 2018.
Time: 9:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate grant applications.
[[Page 60879]]
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892 (Telephone Conference Call).
Contact Person: Frank S. De Silva, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
Activities, Room #3E72A, National Institutes of Health/NIAID, 5601
Fishers Lane, MSC 9823, Rockville, MD 20892-9823, (240) 669-5023,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: November 20, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-25789 Filed 11-26-18; 8:45 am]
BILLING CODE 4140-01-P
